Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies

Virology

Volumn 411, Issue 2, 2011, Pages 416-425

  Emonet, Sebastien E ^a   Urata, Shuzo ^a   De la Torre, Juan C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Arenavirus; Human pathogenic arenaviruses; Reverse genetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BRASSINOSTEROID; ESCRT PROTEIN; JUNIN VIRUS VACCINE; LIVE VACCINE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS VACCINE; MYRISTIC ACID; RECOMBINANT VACCINE; RIBAVIRIN; TRANS ACTING FACTOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS VACCINE;

ANEMIA; ARENAVIRUS; ARENAVIRUS INFECTION; ARGENTINE HEMORRHAGIC FEVER; CYTOPATHOGENIC EFFECT; GENE EXPRESSION; GENETIC PROCEDURES; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; JUNIN VIRUS; LASSA FEVER; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOLECULAR BIOLOGY; NONHUMAN; PICHINDE ARENAVIRUS; PRIORITY JOURNAL; REVERSE GENETICS; REVIEW; RNA REPLICATION; VIRAL GENETICS; VIRAL TROPISM; VIRUS ATTENUATION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS RELEASE; VIRUS REPLICATION; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; GENETIC ENGINEERING; GENETICS, MICROBIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; VIROLOGY; VIRUS REPLICATION;

ARENAVIRUS; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 79952073408     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.01.013     Document Type: Review

References (121)

1. Albarino C.G., Bergeron E., Erickson B.R., Khristova M.L., Rollin P.E., Nichol S.T. Efficient reverse genetics generation of infectious junin viruses differing in glycoprotein processing. J. Virol. 2009, 83(11):5606-5614.
2. Barton L.L., Mets M.B., Beauchamp C.L. Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am. J. Obstet. Gynecol. 2002, 187(6):1715-1716.
3. Bergthaler A., Gerber N.U., Merkler D., Horvath E., de la Torre J.C., Pinschewer D.D. Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog. 2006, 2(6):e51.
4. Beyer W.R., Popplau D., Garten W., von Laer D., Lenz O. Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J. Virol. 2003, 77(5):2866-2872.
5. Blakqori G., Weber F. Efficient cDNA-based rescue of La Crosse bunyaviruses expressing or lacking the nonstructural protein NSs. J. Virol. 2005, 79(16):10420-10428.
6. Bolken T.C., Laquerre S., Zhang Y., Bailey T.R., Pevear D.C., Kickner S.S., Sperzel L.E., Jones K.F., Warren T.K., Amanda Lund S., Kirkwood-Watts D.L., King D.S., Shurtleff A.C., Guttieri M.C., Deng Y., Bleam M., Hruby D.E. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 2006, 69(2):86-97.
7. Borden K.L., Campbell Dwyer E.J., Salvato M.S. An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J. Virol. 1998, 72(1):758-766.
8. Borden K.L., Campbelldwyer E.J., Carlile G.W., Djavani M., Salvato M.S. Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. J. Virol. 1998, 72(5):3819-3826.
9. Bredenbeek P.J., Molenkamp R., Spaan W.J., Deubel V., Marianneau P., Salvato M.S., Moshkoff D., Zapata J., Tikhonov I., Patterson J., Carrion R., Ticer A., Brasky K., Lukashevich I.S. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345(2):299-304.
10. Brunotte L., Lelke M., Hass M., Kleinsteuber K., Becker-Ziaja B., Gunther S. Domain structure of Lassa virus L protein. J. Virol. 2011, 85(1):324-333.
11. Buchmeier M.J., Peters C.J., de la Torre J.C. Arenaviridae: the Virus and Their Replication. Fields Virology 2007, 2:1792-1827. fifth ed.
12. Campbell Dwyer E.J., Lai H., MacDonald R.C., Salvato M.S., Borden K.L. The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner. J. Virol. 2000, 74(7):3293-3300.
13. Cao W., Henry M.D., Borrow P., Yamada H., Elder J.H., Ravkov E.V., Nichol S.T., Compans R.W., Campbell K.P., Oldstone M.B. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998, 282(5396):2079-2081.
14. Carlton J. The ESCRT machinery: a cellular apparatus for sorting and scission. Biochem. Soc. Trans. 2010, 38(6):1397-1412.
15. Carrion R., Patterson J.L., Johnson C., Gonzales M., Moreira C.R., Ticer A., Brasky K., Hubbard G.B., Moshkoff D., Zapata J., Salvato M.S., Lukashevich I.S. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 2007, 25(20):4093-4102.
16. Chen M., Lan S., Ou R., Price G.E., Jiang H., de la Torre J.C., Moskophidis D. Genomic and biological characterization of aggressive and docile strains of lymphocytic choriomeningitis virus rescued from a plasmid-based reverse-genetics system. J. Gen. Virol. 2008, 89(Pt 6):1421-1433.
17. Comai L. Mechanism of RNA polymerase I transcription. Adv. Protein Chem. 2004, 67:123-155.
18. Cornu T.I., de la Torre J.C. RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. J. Virol. 2001, 75(19):9415-9426.
19. Cornu T.I., de la Torre J.C. Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J. Virol. 2002, 76(13):6678-6688.
20. Cornu T.I., Feldmann H., de la Torre J.C. Cells expressing the RING finger Z protein are resistant to arenavirus infection. J. Virol. 2004, 78(6):2979-2983.
21. Damonte E.B., Coto C.E. Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy. Adv. Virus Res. 2002, 58:125-155.
22. Djavani M., Rodas J., Lukashevich I.S., Horejsh D., Pandolfi P.P., Borden K.L., Salvato M.S. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J. Virol. 2001, 75(13):6204-6208.
23. Eckerle L.D., Becker M.M., Halpin R.A., Li K., Venter E., Lu X., Scherbakova S., Graham R.L., Baric R.S., Stockwell T.B., Spiro D.J., Denison M.R. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog. 2010, 6(5):e1000896.
24. Emonet S.F., Garidou L., McGavern D.B., de la Torre J.C. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl Acad. Sci. USA 2009, 106(9):3473-3478.
25. Emonet S.F., Seregin A.V., Yun N.E., Poussard A.L., Walker A.G., de la Torre J.C., Paessler S. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and life-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J. Virol. 2011, 85(4):1473-1483.
26. Enria D.A., Barrera Oro J.G. Junin virus vaccines. Curr. Top. Microbiol. Immunol. 2002, 263:239-261.
27. Eschli B., Quirin K., Wepf A., Weber J., Zinkernagel R., Hengartner H. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. J. Virol. 2006, 80(12):5897-5907.
28. Fearns R., Peeples M.E., Collins P.L. Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. Virology 1997, 236(1):188-201.
29. Fischer S.A., Graham M.B., Kuehnert M.J., Kotton C.N., Srinivasan A., Marty F.M., Comer J.A., Guarner J., Paddock C.D., DeMeo D.L., Shieh W.J., Erickson B.R., Bandy U., DeMaria A., Davis J.P., Delmonico F.L., Pavlin B., Likos A., Vincent M.J., Sealy T.K., Goldsmith C.S., Jernigan D.B., Rollin P.E., Packard M.M., Patel M., Rowland C., Helfand R.F., Nichol S.T., Fishman J.A., Ksiazek T., Zaki S.R. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 2006, 354(21):2235-2249.
30. Fisher-Hoch S.P., Hutwagner L., Brown B., McCormick J.B. Effective vaccine for lassa fever. J. Virol. 2000, 74(15):6777-6783.
31. Flatz L., Bergthaler A., de la Torre J.C., Pinschewer D.D. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl Acad. Sci. USA 2006, 103(12):4663-4668.
32. Flatz L., Hegazy A.N., Bergthaler A., Verschoor A., Claus C., Fernandez M., Gattinoni L., Johnson S., Kreppel F., Kochanek S., Broek M., Radbruch A., Levy F., Lambert P.H., Siegrist C.A., Restifo N.P., Lohning M., Ochsenbein A.F., Nabel G.J., Pinschewer D.D. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat. Med. 2010, 16(3):339-345.
33. Freed E.O. Viral late domains. J. Virol. 2002, 76(10):4679-4687.
34. Gallaher W.R., DiSimone C., Buchmeier M.J. The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol. 2001, 1:1.
35. Garcin D., Kolakofsky D. A novel mechanism for the initiation of Tacaribe arenavirus genome replication. J. Virol. 1990, 64(12):6196-6203.
36. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., Grolla A., Stroher U., Fernando L., Daddario K.M., Guttieri M.C., Mothe B.R., Larsen T., Hensley L.E., Jahrling P.B., Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005, 2(6):e183.
37. Groseth A., Feldmann H., Theriault S., Mehmetoglu G., Flick R. RNA polymerase I-driven minigenome system for Ebola viruses. J. Virol. 2005, 79(7):4425-4433.
38. Habjan M., Penski N., Spiegel M., Weber F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J. Gen. Virol. 2008, 89(Pt 9):2157-2166.
39. Halfmann P., Kim J.H., Ebihara H., Noda T., Neumann G., Feldmann H., Kawaoka Y. Generation of biologically contained Ebola viruses. Proc. Natl Acad. Sci. USA 2008, 105(4):1129-1133.
40. Hass M., Golnitz U., Muller S., Becker-Ziaja B., Gunther S. Replicon system for Lassa virus. J. Virol. 2004, 78(24):13793-13803.
41. Hass M., Lelke M., Busch C., Becker-Ziaja B., Gunther S. Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome. J. Virol. 2008, 82(20):10207-10217.
42. Hass M., Westerkofsky M., Muller S., Becker-Ziaja B., Busch C., Gunther S. Mutational analysis of the lassa virus promoter. J. Virol. 2006, 80(24):12414-12419.
43. Hawkins J.L., Robbins M.D., Warren L.C., Xia D., Petras S.F., Valentine J.J., Varghese A.H., Wang I.K., Subashi T.A., Shelly L.D., Hay B.A., Landschulz K.T., Geoghegan K.F., Harwood H.J. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J. Pharmacol. Exp. Ther. 2008, 326(3):801-808.
44. Hay B.A., Abrams B., Zumbrunn A.Y., Valentine J.J., Warren L.C., Petras S.F., Shelly L.D., Xia A., Varghese A.H., Hawkins J.L., Van Camp J.A., Robbins M.D., Landschulz K., Harwood H.J. Aminopyrrolidineamide inhibitors of site-1 protease. Bioorg. Med. Chem. Lett. 2007, 17(16):4411-4414.
45. Hermann T. Strategies for the design of drugs targeting RNA and RNA-protein complexes. Angew. Chem. Int. Ed Engl. 2000, 39(11):1890-1904.
46. Hermann T., Westhof E. Rational drug design and high-throughput techniques for RNA targets. Comb. Chem. High Throughput Screen. 2000, 3(3):219-234.
47. Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin. Infect. Dis. 2001, 33(10):1707-1712.
48. Kawaoka Y.E. Biology of negative strand RNA viruses: the power of reverse genetics. Curr. Top. Microbiol. Immunol. 2004, 283.
49. Kranzusch P.J., Schenk A.D., Rahmeh A.A., Radoshitzky S.R., Bavari S., Walz T., Whelan S.P. Assembly of a functional Machupo virus polymerase complex. Proc. Natl Acad. Sci. USA 2010, 107(46):20069-20074.
50. Kunz S., Borrow P., Oldstone M.B. Receptor structure, binding, and cell entry of arenaviruses. Curr. Top. Microbiol. Immunol. 2002, 262:111-137.
51. Kunz S., Edelmann K.H., de la Torre J.C., Gorney R., Oldstone M.B. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 2003, 314(1):168-178.
52. Kunz S., Sevilla N., Rojek J.M., Oldstone M.B. Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus. Virology 2004, 325(2):432-445.
53. Lan S., McLay Schelde L., Wang J., Kumar N., Ly H., Liang Y. Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J. Virol. 2009, 83(13):6357-6362.
54. Lee A.M., Rojek J.M., Spiropoulou C.F., Gundersen A.T., Jin W., Shaginian A., York J., Nunberg J.H., Boger D.L., Oldstone M.B., Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 2008, 283(27):18734-18742.
55. Lee J.S., Hadjipanayis A.G., Parker M.D. Viral vectors for use in the development of biodefense vaccines. Adv. Drug Deliv. Rev. 2005, 57(9):1293-1314.
56. Lee K.J., Novella I.S., Teng M.N., Oldstone M.B., de La Torre J.C. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 2000, 74(8):3470-3477.
57. Lelke M., Brunotte L., Busch C., Gunther S. An N-terminal region of Lassa virus L protein plays a critical role in transcription but not replication of the virus genome. J. Virol. 2010, 84(4):1934-1944.
58. Lenz O., ter Meulen J., Klenk H.D., Seidah N.G., Garten W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl Acad. Sci. USA 2001, 98(22):12701-12705.
59. Liang Y., Lan S., Ly H. Molecular determinants of Pichinde virus infection of guinea pigs-a small animal model system for arenaviral hemorrhagic fevers. Ann. NY Acad. Sci. 2009, 1171(Suppl 1):E65-E74.
60. Lopez N., Jacamo R., Franze-Fernandez M.T. Transcription and RNA replication of tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. J. Virol. 2001, 75(24):12241-12251.
61. Lowen A.C., Noonan C., McLees A., Elliott R.M. Efficient bunyavirus rescue from cloned cDNA. Virology 2004, 330(2):493-500.
62. Luytjes W., Krystal M., Enami M., Parvin J.D., Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 1989, 59(6):1107-1113.
63. Maiztegui J.I., McKee K.T., Barrera Oro J.G., Harrison L.H., Gibbs P.H., Feuillade M.R., Enria D.A., Briggiler A.M., Levis S.C., Ambrosio A.M., Halsey N.A., Peters C.J. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J. Infect. Dis. 1998, 177(2):277-283.
64. Martinez-Sobrido L., Emonet S., Giannakas P., Cubitt B., Garcia-Sastre A., de la Torre J.C. Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 2009, 83(21):11330-11340.
65. Martinez-Sobrido L., Garcia-Sastre A. Generation of recombinant influenza virus from plasmid DNA. J. Vis. Exp. 2010, 42.
66. Martinez-Sobrido L., Giannakas P., Cubitt B., Garcia-Sastre A., de la Torre J.C. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 2007, 81(22):12696-12703.
67. Martinez-Sobrido L., Zuniga E.I., Rosario D., Garcia-Sastre A., de la Torre J.C. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 2006, 80(18):9192-9199.
68. McKee K.T., Oro J.G., Kuehne A.I., Spisso J.A., Mahlandt B.G. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 1992, 34(3):154-163.
69. Merkler D., Horvath E., Bruck W., Zinkernagel R.M., Del la Torre J.C., Pinschewer D.D. "Viral deja vu" elicits organ-specific immune disease independent of reactivity to self. J. Clin. Invest. 2006, 116(5):1254-1263.
70. Meyer B.J., Southern P.J. Sequence heterogeneity in the termini of lymphocytic choriomeningitis virus genomic and antigenomic RNAs. J. Virol. 1994, 68(11):7659-7664.
71. Morin B., Coutard B., Lelke M., Ferron F., Kerber R., Jamal S., Frangeul A., Baronti C., Charrel R., de Lamballerie X., Vonrhein C., Lescar J., Bricogne G., Gunther S., Canard B. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. PLoS Pathog. 2010, 6(9).
72. Morita E., Colf L.A., Karren M.A., Sandrin V., Rodesch C.K., Sundquist W.I. Human ESCRT-III and VPS4 proteins are required for centrosome and spindle maintenance. Proc. Natl Acad. Sci. USA 2010, 107(29):12889-12894.
73. Neuman B.W., Adair B.D., Burns J.W., Milligan R.A., Buchmeier M.J., Yeager M. Complementarity in the supramolecular design of arenaviruses and retroviruses revealed by electron cryomicroscopy and image analysis. J. Virol. 2005, 79(6):3822-3830.
74. Neumann G., Kawaoka Y. Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA. Curr. Top. Microbiol. Immunol. 2004, 283:43-60.
75. Ogawa Y., Sugiura K., Kato K., Tohya Y., Akashi H. Rescue of Akabane virus (family Bunyaviridae) entirely from cloned cDNAs by using RNA polymerase I. J. Gen. Virol. 2007, 88(Pt 12):3385-3390.
76. Oldstone M.B. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr. Top. Microbiol. Immunol. 2002, 263:83-117.
77. Palacios G., Druce J., Du L., Tran T., Birch C., Briese T., Conlan S., Quan P.L., Hui J., Marshall J., Simons J.F., Egholm M., Paddock C.D., Shieh W.J., Goldsmith C.S., Zaki S.R., Catton M., Lipkin W.I. A new arenavirus in a cluster of fatal transplant-associated diseases. N. Engl. J. Med. 2008, 358(10):991-998.
78. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res. 2005, 107(2):165-171.
79. Perez M., Craven R.C., de la Torre J.C. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl Acad. Sci. USA 2003, 100(22):12978-12983.
80. Perez M., de la Torre J.C. Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 2003, 77(2):1184-1194.
81. Perez M., Greenwald D.L., de la Torre J.C. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J. Virol. 2004, 78(20):11443-11448.
82. Peters C.J. Human infection with arenaviruses in the Americas. Curr. Top. Microbiol. Immunol. 2002, 262:65-74.
83. Pinschewer D.D., Perez M., de la Torre J.C. Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J. Virol. 2003, 77(6):3882-3887.
84. Pinschewer D.D., Perez M., de la Torre J.C. Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J. Virol. 2005, 79(7):4519-4526.
85. Pinschewer D.D., Perez M., Sanchez A.B., de la Torre J.C. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl Acad. Sci. USA 2003, 100(13):7895-7900.
86. Pinschewer D.D., Schedensack M., Bergthaler A., Horvath E., Bruck W., Lohning M., Merkler D. T cells can mediate viral clearance from ependyma but not from brain parenchyma in a major histocompatibility class I- and perforin-independent manner. Brain 2010, 133(Pt 4):1054-1066.
87. Poch O., Sauvaget I., Delarue M., Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 1989, 8(12):3867-3874.
88. Pushko P., Geisbert J., Parker M., Jahrling P., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 2001, 75(23):11677-11685.
89. Qi X., Lan S., Wang W., Schelde L.M., Dong H., Wallat G.D., Ly H., Liang Y., Dong C. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 2010, 468(7325):779-783.
90. Racaniello V.R., Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 1981, 214(4523):916-919.
91. Radoshitzky S.R., Abraham J., Spiropoulou C.F., Kuhn J.H., Nguyen D., Li W., Nagel J., Schmidt P.J., Nunberg J.H., Andrews N.C., Farzan M., Choe H. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 2007, 446(7131):92-96.
92. Raju R., Raju L., Hacker D., Garcin D., Compans R., Kolakofsky D. Nontemplated bases at the 5' ends of Tacaribe virus mRNAs. Virology 1990, 174(1):53-59.
93. Rodriguez-Carreno M.P., Nelson M.S., Botten J., Smith-Nixon K., Buchmeier M.J., Whitton J.L. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 2005, 335(1):87-98.
94. Rojek J.M., Kunz S. Cell entry by human pathogenic arenaviruses. Cell. Microbiol. 2008, 10(4):828-835.
95. Rojek J.M., Lee A.M., Nguyen N., Spiropoulou C.F., Kunz S. Site 1 protease is required for proteolytic processing of the glycoproteins of the South American hemorrhagic fever viruses Junin, Machupo, and Guanarito. J. Virol. 2008, 82(12):6045-6051.
96. Rojek J.M., Pasqual G., Sanchez A.B., Nguyen N.T., de la Torre J.C., Kunz S. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 2010, 84(1):573-584.
97. Sakai J., Nohturfft A., Goldstein J.L., Brown M.S. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J. Biol. Chem. 1998, 273(10):5785-5793.
98. Sanchez A.B., de la Torre J.C. Genetic and biochemical evidence for an oligomeric structure of the functional L polymerase of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 2005, 79(11):7262-7268.
99. Sanchez A.B., de la Torre J.C. Rescue of the prototypic Arenavirus LCMV entirely from plasmid. Virology 2006, 350(2):370-380.
100. Saunders A.A., Ting J.P., Meisner J., Neuman B.W., Perez M., de la Torre J.C., Buchmeier M.J. Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J. Virol. 2007, 81(11):5649-5657.
101. Schneider U., Schwemmle M., Staeheli P. Genome trimming: a unique strategy for replication control employed by Borna disease virus. Proc. Natl Acad. Sci. USA 2005, 102(9):3441-3446.
102. Seidah N.G., Khatib A.M., Prat A. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol. Chem. 2006, 387(7):871-877.
103. Sousa R., Mukherjee S. T7 RNA polymerase. Prog. Nucleic Acid Res. Mol. Biol. 2003, 73:1-41.
104. Strecker T., Eichler R., Meulen J., Weissenhorn W., Dieter Klenk H., Garten W., Lenz O. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J. Virol. 2003, 77(19):10700-10705.
105. Strecker T., Maisa A., Daffis S., Eichler R., Lenz O., Garten W. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virol. J. 2006, 3:93.
106. Subbarao K., Katz J.M. Influenza vaccines generated by reverse genetics. Curr. Top. Microbiol. Immunol. 2004, 283:313-342.
107. Sucheck S.J., Greenberg W.A., Tolbert T.J., Wong C.H. Design of small molecules that recognize RNA: development of aminoglycosides as potential antitumor agents that target oncogenic RNA sequences. Angew. Chem. Int. Ed Engl. 2000, 39(6):1080-1084.
108. Sucheck S.J., Wong C.H. RNA as a target for small molecules. Curr. Opin. Chem. Biol. 2000, 4(6):678-686.
109. Taniguchi T., Palmieri M., Weissmann C. QB DNA-containing hybrid plasmids giving rise to QB phage formation in the bacterial host. Nature 1978, 274(5668):223-228.
110. Tortorici M.A., Albarino C.G., Posik D.M., Ghiringhelli P.D., Lozano M.E., Rivera Pomar R., Romanowski V. Arenavirus nucleocapsid protein displays a transcriptional antitermination activity in vivo. Virus Res. 2001, 73(1):41-55.
111. Urata S., Noda T., Kawaoka Y., Yokosawa H., Yasuda J. Cellular factors required for Lassa virus budding. J. Virol. 2006, 80(8):4191-4195.
112. Urata S., Yun N., Pasquato A., Paessler S., Kunz S., de la Torre J.C. Antiviral activity of a small molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 2011, 85(2):795-803.
113. Vieth S., Torda A.E., Asper M., Schmitz H., Gunther S. Sequence analysis of L RNA of Lassa virus. Virology 2004, 318(1):153-168.
114. Volpon L., Osborne M.J., Capul A.A., de la Torre J.C., Borden K.L. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E. Proc. Natl Acad. Sci. USA 2010, 107(12):5441-5446.
115. von Messling V., Cattaneo R. Toward novel vaccines and therapies based on negative-strand RNA viruses. Curr. Top. Microbiol. Immunol. 2004, 283:281-312.
116. Wang S., Huber P.W., Cui M., Czarnik A.W., Mei H.Y. Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. Biochemistry 1998, 37(16):5549-5557.
117. Wang Y., Hamasaki K., Rando R.R. Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region. Biochemistry 1997, 36(4):768-779.
118. Wilson W.D., Li K. Targeting RNA with small molecules. Curr. Med. Chem. 2000, 7(1):73-98.
119. York J., Nunberg J.H. Role of the stable signal peptide of Junin arenavirus envelope glycoprotein in pH-dependent membrane fusion. J. Virol. 2006, 80(15):7775-7780.
120. York J., Romanowski V., Lu M., Nunberg J.H. The signal peptide of the Junin arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J. Virol. 2004, 78(19):10783-10792.
121. Zinkernagel R.M. Lymphocytic choriomeningitis virus and immunology. Curr. Top. Microbiol. Immunol. 2002, 263:1-5.